Líffræðifélag Íslands - biologia.is
Líffræðiráðstefnan 2017
Erindi/veggspjald / Talk/poster V30
Höfundar / Authors: Níels Árni Árnason (1), Ragna Landrö (1), Óttar Rolfsson (2), Björn Harðarson (1), Sveinn Guðmundsson (1) and Ólafur E. Sigurjónsson (1, 3)
Starfsvettvangur / Affiliations: 1. The blood bank, Landspitali-The National University Hospital of Iceland , 2 . Center for systems biology, University of Iceland, 3. School of Science and Engineering; Reykjavik University
Kynnir / Presenter: Níels Árni Árnason
Backround.
Platelets concentrates can be stored for a maximum of 5-7 days due to risk of pathogen contamination and platelet storage lesion (PSL). PSL is a collective term of variety of factors that contribute to the deterioration of platelet quality during storage. To reduce the risk of pathogen contamination, methods have been developed that render pathogens inactive (PI) in platelet concentrates prior to storage. Several reports support the notion of miRNA being important in platelet function. Changes in the regulation of specific miRNA’s during storage have been reported as well as perturbation effects related to pathogen inactivation methods.
Aim.
To investigate the effects of PI on selected miRNAs in buffy coat generated platelets stored for 7 days under standard blood banking conditions.
Study design and methods
Using a pool and split strategy 4 identical single dose units where generated that originated from 24 whole blood donors (n=8). Each sister unit received different treatment (Intercept/Control-SSP+/Irradiated in plasma/Control-Plasma). In vitro quality of platelets was monitored on day 1, 2, 4 and 7 during storage using and selected miRNA were analysed using QPCR.
Results.
Out of the 30 miRNA analyzed only three showed a significant difference at one or more time points as a result of different treatment. On day 7 miR1260a and miR1260b where down regulated in groups Control-SSP+,Control-Plasma and Irradiated,Control-Plasma respectively when compared to day 1 baseline samples. miR-96-5p was down regulated on day 2 and 4 in the Intercept group compared to Control-SSP+.
Conclusion
The INTERCEPT treatment does not change the quality or significantly alters the miRNA profile of platelet concentrates generated and stored using standard blood banking condition.